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1,3-Butadiene (BD) is a highly volatile four-
carbon chemical [C4H6; Chemical Abstracts
Service (CAS) no. 106-99-0] made from
petroleum processing. It is a colorless, flam-
mable gas that is widely used in the produc-
tion of rubber and thermoplastic resins
(Morrow 1990). Its annual worldwide pro-
duction is approximately 12 billion pounds,
with 1.6 billion pounds produced in China
(Cui 2003). Following the United States,
China is now the second leading producer and
consumer of BD. While useful for industry,
BD is also an environmental air pollutant
commonly found in automobile exhaust and
cigarette smoke.
BD is a potent carcinogen at several sites
in mice and rats after inhalation exposure.
Results from exposures in rodent studies indi-
cate species differences in carcinogenic sus-
ceptibility between mice and rats: B6C3F1
mice were observed to be more sensitive to
BD-induced carcinogenicity than Sprague-
Dawley rats (Huff et al. 1985; Glaister and
Owen 1990; Owen et al. 1987). While the
species and individual susceptibilities to DNA
damage appear to differ greatly among mice,
rats, and humans, it has been strongly sug-
gested that the mutagenicity and carcino-
genicity of BD are related to its metabolic
activation in several DNA-reactive intermedi-
ates, including 1,2-epoxy-3-butene (EB),
1,2,3,4-diepoxybutane (DEB), and 3,4-
epoxy-1,2-butanediol (EB-diol) (Richardson
et al. 1999).
Although research has shown that BD is a
potent animal carcinogen, only a few studies
have indicated that BD is a probable human
carcinogen. In several epidemiologic studies,
occupational exposure to BD is believed to be
associated with excess mortality from lym-
phatic and hematopoietic cancers (Delzell
et al. 1996; Divine and Hartman 1996).
Overall, the epidemiologic findings in BD-
exposed workers suggest, but do not prove,
that it is a human carcinogen (Zhang et al.
2004). BD had been classified in Group 2A
(probably carcinogenic to humans) by the
International Agency for Research on Cancer
(IARC 1992), but several regulatory agencies
have recently considered raising its status to
Group 1 (carcinogenic to humans) on the
basis of the emerging data (Acquavella and
Leonard 2001; IARC 1999; Morrow 2001).
In a recent study of mortality among workers
in the North American synthetic rubber
industry, Cheng et al. (2007) found the pres-
ence of a causal relationship between high
cumulative exposure and high-intensity expo-
sure to BD and leukemia. The weight of this
evidence led to the recent classiﬁcation of BD
as a Group 1 known human carcinogen by
the IARC Working Group (IARC, in press).
Measuring mutation frequency (MF) at
the hypoxanthine–guanine–phosphoribosyl-
transferase (HPRT) locus as an intermediate
biomarker of BD carcinogenicity could be a
powerful complement to traditional methods
based on mortality and cancer incidence. MF
of the HPRT gene as a biomarker of genotoxi-
city has been investigated in BD-exposed
humans, but the findings are inconsistent.
Three studies of BD-exposed workers in a
Texas facility conducted by one laboratory
indicated HPRT mutations in blood lympho-
cytes using the autoradiographic assay
(Ammenheuser et al. 2001; Ward et al. 1994,
1996, 2001). In contrast, studies by Hayes
et al. (1996) and Tates et al. (1996) using the
T-cell cloning assay, failed to ﬁnd signiﬁcant
increases in MF in blood lymphocytes of
BD-exposed Chinese and Czech workers, even
though BD exposure concentrations were sim-
ilar to those detected in the Texas studies.
Furthermore, no increase in MF was found in
the studies by Albertini et al. (2001) using
both the autoradiographic and T-cell cloning
assays followed by the T-cell cloning assay in
the follow-up HPRT mutation study
(Albertini et al. 2007). It is important to note
that in the early studies, the HPRT autoradio-
graphic assay was consistently used, whereas in
later and follow-up studies, the T-cell cloning
assay or a combination of the two assays was
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BACKGROUND: 1,3-Butadiene (BD) is an important industrial chemical and an environmental and
occupational pollutant. The carcinogenicity of BD in rodents has been proved, but its carcinogenic
and mutagenic molecular mechanism(s) are not fully elucidated in humans.
OBJECTIVES: In the present study, we compared the mutation frequencies and exon deletions of
BD-exposed workers with that of control subjects in China to identify the characteristic mutations
associated with BD exposure in the human HPRT (hypoxanthine–guanine–phosphoribosyltrans-
ferase) gene.
METHODS: Seventy-four workers exposed to BD via inhalation and 157 matched controls were
evaluated in Nanjing, China. Molecular analysis of HPRT mutant T lymphocytes from BD-
exposed workers and nonexposed control subjects was conducted to identify changes in the struc-
ture of the HPRT gene. A total of 783 HPRT mutants were analyzed by multiplex polymerase
chain reaction, in which 368 HPRT mutants were isolated from BD-exposed workers and 415
mutants from control subjects.
RESULTS: The BD-exposed workers showed a higher mutation frequency (18.2 ± 9.4 × 10–6) than
the control subjects (12.7 ± 7.3 × 10–6), but the difference was not signiﬁcant (p > 0.05). The fre-
quency of exon deletions in BD-exposed workers (27.4%) was signiﬁcantly higher than that in con-
trol subjects (12.5%) (p < 0.05), which mainly included multiplex exon deletions (2–8 exons).
CONCLUSIONS: The results of the present study suggest that BD should increase the frequency of
large deletions of HPRT gene in human lymphocytes This change conﬁrms and supports the previ-
ous ﬁndings in BD-exposed workers.
KEY WORDS: 1,3-butadiene, BD, exon deletion, HPRT gene, lymphocyte, occupational exposure.
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[Online 12 November 2007]used. It is possible that differences in the sensi-
tivity of the methods and the target cells may
have resulted in contradictory findings. For
cytogenetic effects, the Czech study found a
signiﬁcant increase in chromosomal aberration
frequencies and sister chromatid exchanges
(SCEs) in the BD-exposed workers (Sram
et al. 1998). However, subsequent studies by
Sram et al. (2004) and Albertini et al. (2001,
2003, 2007) failed to confirm this finding.
The current consensus on existing data is that
BD does not cause cytogenetic effects in
humans, most likely because DEB is not
formed at sufﬁcient levels in humans to play a
role in its carcinogenicity. Thus, the remain-
ing open question is whether BD is mutagenic
in humans.
At the BD exposure levels encountered in
modern industry, a recent large study failed to
demonstrate either induction of HPRT muta-
tions or cytogenetic changes, even though
measurable levels of electrophilic BD metabo-
lites were produced in vivo (Albertini et al.
2007). Studies of workers at higher exposure
levels are required to clarify the question of
genotoxicity, which is the important qualita-
tive non-tumor end point for making human
cancer risk assessments for BD (Albertini et al.
2003). In the present study, we analyzed a
large population of BD-exposed workers and
nonexposed control subjects from Yangzi
Petrochemical Products Company in Nanjing,
China, to determine the MF of the HPRT
gene in lymphocytes. We then compared the
differences in the exon deletions to help us
understand the mechanisms responsible for
the mutagenicity of BD.
Materials and Methods
Subject selection and specimen collection. The
large population study was initiated in 2002
at Yangzi Petrochemical Products Co. in
Nanjing, China. All subjects worked at the
alkenes plant of this company. A total of
237 subjects were included in the study.
Among them, 80 subjects from the BD pro-
duction workshop were categorized into the
BD-exposed group, of which 74 subjects
(92.5%) finished the evaluations. For com-
parision, 157 subjects from the administrative
office and the vapor workshop of the same
plant were enrolled as members of the control
group, and all the control subjects (100%)
finished the evaluations. The subjects in the
BD-exposed group and the control group
were matched for age and sex.
Questionnaires and blood samples for all
subjects were accompanied by regular physical
examinations once every 2 years at the Yangzi
Employee Hospital. An informed consent
document was signed by each subject after the
procedures and the purpose of the study were
explained. All subjects were asked to complete
a questionnaire to gather information on sex;
age; employment history; chemical exposure;
history of the use of tobacco, alcohol, and
caffeine-containing beverages; recent illnesses;
general health; and medications, etc.
A 15-mL blood sample was collected from
each subject in the Yangzi Employee Hospital.
Blood samples were stored at room temperature
in an insulated container and were delivered to
the laboratory within 12 hr of collection.
Exposure assessment. Because of the pro-
duction process for BD and the activities of
workers during the work shift, 10 locations in
the BD production workshop were chosen for
air sampling, including the areas for procedure
control, the analytical laboratory, product
storage, and the pipeline. The individuals in
the BD-exposed group worked 8 hr/day,
4 days/week. Except for regular sampling
(once every 4 hr) and circuit inspection (once
per hour), the workers in the BD production
workshop stayed in the procedure control cen-
ter or the analytical laboratory while they were
on duty. According to the typical workers’ rou-
tines, it was estimated that the duration of time
spent in the product storage and pipeline areas
was no more than 1 hr/day, or 300 hr/year, for
each worker. For comparison with the produc-
tion locations, two locations—one in the
administrative office and one in the vapor
workshop of the same plant—were chosen for
air sampling in the control group.
For each sampling location, an air sampler
(Gillian Instrument Corp., Wayne, NJ, USA)
collected air samples once a day for 3 consec-
utive days. The air was drawn through char-
coal tubes using a sampling pump, and a total
of 4 L of air were collected at a flow rate of
0.2 L/min for each sample. After sampling,
each charcoal tube collected was desorbed in
dichloromethane alkyl, and the samples were
analyzed quantitatively for BD using a gas
chromatograph ﬁtted with a ﬂame inozation
detector (Beijing Analytical Instrument
Factory, Beijing, China) according to the
standard operation procedure.
HPRT mutation assay and mutant expan-
sion. We selected the T-cell cloning assay as the
HPRT mutation assay for our study; the
method has been described previously (Ma
et al. 2000). Brieﬂy, Ficoll reagent (Haoyang
Biological Manufacture Co., Tianjin, China)
was used to isolate the peripheral lymphocytes
from whole blood by density centrifugation.
The isolated lymphocytes were stimulated for
48 hr in RPMI 1640 medium supplemented
with 2 µg/mL purified phytohemagglutinin
(PHA-M; Gibco/BRL Life Technologies Inc.,
Rockville, MD, USA), 20% HL-1 medium
(Bio-Whittaker Inc., Walkersville, MD, USA),
and 10% bovine calf serum (BCS; Gibco/BRL
Life Technologies Inc.). The lymphocytes were
then counted and seeded at 1 × 104 viable cells
per well in round-bottomed 96-well micro-well
plates with RPMI 1640 medium supplemented
with reduced PHA-M (1 µg/mL), 10% human
T-stim (Collaborative Biomedical Products,
Bedford, MA, USA), 20% HL-1 medium, and
15% BCS. The cells were cultured together
with an equal number of irradiated lym-
phoblastoid feeder cells (irradiation was 50 Gy
Cobalt-60). To determine the cloning effi-
ciency (CE), lymphocytes were plated at densi-
ties of one and two cells per well in the absence
of 6-thioguanine (6-TG). To determine the
MF, the remaining cells were plated at 1 × 104
viable cells per well in the presence of 6-TG
(Sigma-Aldrich Chemical Co., St. Louis, MO,
USA). All the plates were incubated at 37°C
in a humidified 5% CO2 atmosphere for
10–14 days to determine CE, or to select the
HPRT mutant clones and determine MF. CE
was calculated using Poisson distribution analy-
sis: CE = –ln P0/N, where P0 was the fraction of
wells negative for colony growth and N was the
average number of cells originally inoculated
per well by limiting dilution. The thioguanine-
selected CE divided by the mean unselected CE
yields the MF.
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Table 1. BD exposure doses in work locations of the BD-exposed and control groups.
No. of  No. below the minimum exposure
Groups Locations samples dose that can be measureda Exposure range (ppm) χ – ± SD (ppm) Historical record (ppm)
BD-exposed 10 30 4 0–83.1 9.7 ± 15.7 0–24.9
BD-exposed without 10 29 4 0–25.8 7.2 ± 7.6
the highest sample
Control 2 6 6 Could not be measureda Could not be measureda Could not be measureda
aThe minimum exposure dose that could be measured depended on the analytical method. In this study it was 0.2 ppm.
Figure 1. BD exposure dose at each sampling loca-
tion of the BD-exposed group.
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Sample 3Mutant lymphocyte clones were identiﬁed
with an inverted microscope (Olympus,
Tokyo, Japan). All the mutant clones were
selected for expansion, and the culture
medium for expansion was the same as that
for the initial culture in 96-well plates. Mutant
clones were expanded first from one well of
96-well plates to 24-well plates, then to 6- or
12-well culture plates. Only the clones that
expanded successfully to ≥1 × 106 cells were
collected for DNA isolation, and the aliquots
were frozen for further molecular analysis.
Isolation of DNA. All wells of an
expanded mutant clone were pooled and har-
vested for the isolation of DNA. A wizard
genomic DNA purification kit (Promega
Corp., Madison, WI, USA) was used to isolate
DNA from cells; the isolation was performed
according to the procedure of Ma et al.
(2000). Simultaneously, normal lymphocytes
were collected to isolate DNA to serve as con-
trols for the further molecular analysis.
Multiplex PCR amplification of the
HPRT gene. Exon loss and changes in the
size of each exon were identiﬁed by multiplex
polymerase chain reaction (PCR) directly,
and these changes were deﬁned as exon dele-
tions of the HPRT gene. If the number of
exon deletions were ≥ 2 (2–9 exons), they
were considered large deletions. All expanded
HPRT mutant clones were analyzed by a mul-
tiplex PCR assay to detect exon deletions.
Multiplex PCR ampliﬁcation of the HPRT
gene was performed as previously described
(Liu et al. 2003), with slight modifications.
Nine HPRT exons were ampliﬁed simultane-
ously using eight pairs of PCR primers; exons 7
and 8 were ampliﬁed as a single PCR product.
For ampliﬁcation of HPRT exons, the genomic
DNA template (36–50 ng) was mixed with
50 pmol of each primer pair in a total reaction
volume of 50 µL, containing 50 mM KCl,
10 mM Tris–HCl (pH 8.8), 0.3–1.05 mM
MgCl2, 0.2 mM deoxy-nucleotide triphos-
phate, and 2.5 U of Amplitaq DNA poly-
merase (Shenggong Chemical Co., Shanghai,
China). After initial denaturation of the tem-
plate DNA at 98°C for 7 min, a total of
40 PCR cycles were performed with denatura-
tion at 94°C for 1.5 min, annealing at 52°C for
1.5 min and extension at 72°C for 2.0 min.
Exon 1 was synthesized individually with modi-
ﬁed conditions: a total of 30 PCR cycles were
performed with denaturation at 95°C for
0.5 min, annealing at 64°C for 1.0 min and
extension at 72°C for 1 min. The last cycle was
ﬁnished with a 7-min extension at 72°C. The
PCR product (10 µL) was analyzed by 3%
agarose gel electrophoresis or 5% polyacry-
lamide gel electrophoresis.
Statistical analysis. The differences in the
HPRT mutant frequency and cloning effi-
ciency between the two study groups were
analyzed by the Student t-test. These statistical
evaluations were performed with SPSS 11.0
for Windows (SPSS Inc., Chicago, IL, USA).
Results
Exposure assessment. In the present study the
minimum exposure to BD that could be
measured with our equipment was 0.2 ppm.
All 30 samples evaluated at the 10 locations of
the BD-exposed group ranged from 0 to
83.1 ppm; among them, four samples could
not be measured, which meant their values
were < 0.2 ppm (Figure 1; Table 1). The sam-
ple with the highest concentration of BD
(83.1 ppm) was collected from the sewer exit
in the workshop and was only observed once.
When all data from three samplings were
considered, the average BD exposure was
9.7 ± 15.7 ppm. If the highest value was
ignored, the other 29 samples ranged from
0 to 25.8 ppm, and the average value was
7.2 ± 7.6 ppm in the exposed areas. All sam-
ples evaluated at the control group locations
were below the minimum exposure that could
be measured (< 0.2 ppm). The data of BD
exposure in this study were consistent with
the historical records from 1991 to 2001 in
this workshop.
Study subjects and MF. On the basis of the
information collected using the questionnaire,
BD-exposed workers (n = 74) and control sub-
jects (n = 157) had similar demographic charac-
teristics (Table 2), including sex, age, and
duration of employment. The mean age for
BD-exposed workers and control subjects was
30.7 and 34.8 years of age, respectively. None
of the female subjects in either group smoked,
but the proportions of male smokers were
36.5% in the BD-exposed group and 33.8% in
the control group, respectively. There were no
signiﬁcant differences found in smoking, con-
sumption of alcohol, or consumption of
caffeine-containing beverages between BD-
exposed workers and control subjects.
The lymphocyte cloning efficiencies and
the frequencies of mutants of the study popu-
lation are listed in Table 3. There was a non-
significant difference in CE between the
BD-exposed workers and control subjects.
The MF of BD-exposed workers was 18.2 ±
9.4 (× 10–6), which was higher than the
12.7 ± 7.3 (× 10–6) for the control subjects,
but this difference was not significant
(p > 0.05). The mean numbers of mutants per
subject were 8 in the BD-exposed group and
6 in the control group.
Exon deletions detected by multiplex PCR.
We analyzed a total of 783 HPRT mutants by
multiplex PCR, including 368 mutants from
BD-exposed workers and 415 mutants from
control subjects. Results of the exon deletions
detected by multiplex PCR are summarized in
Table 4. A schematic of the distribution of
deleted exons in mutants is presented in
Figure 2, which shows that 630 mutant clones
HPRT mutation in butadiene-exposed workers
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Table 2. Selected demographic characteristics of study subjects.
Characteristic Control [n (%)] BD-exposed [n (%)]
No. enrolled 157 80
No. evaluated 157 (100) 74 (92.5)
Sex
Male 110 (70.1) 54 (73.0)
Female 47 (29.9) 20 (27.0)
Age (years)
20–30  62 (39.5) 32 (43.2)
30–40  87 (55.4) 39 (52.7)
≥ 41 8 (5.1) 3 (4.1)
χ – ± SD 34.8 ± 8.2 30.7 ± 6.7
Duration of employment
≤ 5 years 61 (38.9) 31 (41.9)
> 5 years 96 (61.1) 43 (58.1)
Tobacco use 53 (33.8) 27 (36.5)
Alcohol use 41 (26.1) 19 (25.7)
Tea use 28 (17.8) 15 (20.3)
Table 3. Molecular analysis of the HPRT mutant lymphocytes.
Control BD-exposed
Factor n (range) χ – ±S D n (range) χ – ±S D
Cloning efﬁciency (%) 157 32.0 ± 11.6 74 31.6 ± 9.2
Mutation frequency ( × 10–6) 157 12.7 ± 7.3 74 18.2 ± 9.4
Mean number of mutants per subject 6 (1–15) 8 (3–19)
Table 4. Exon deletions in the HPRT gene of human
T-lymphocytes.
Control BD-exposed
Type of deletion [n (%)] [n (%)]
Total clones with deletions 52 (12.5) 101 (27.4)*
All exons deletion (9) 4 (1.0) 9 (2.4)
Multiple exon deletions (2–8) 23 (5.5) 56 (15.2)*
Continuous deletions 17 (4.1) 37 (10.1)*
Discontinuous deletions 6 (1.4) 19 (5.2)*
Single exon deletions (1) 25 (6.0) 36 (9.8)
Other mutations 363 (87.5) 267 (72.6)
Total clones analyzed 415 (100) 368 (100)
*Significantly increased compared with control subjects
(p < 0.05).ampliﬁed all nine exons after multiplex PCR
analysis, indicating these clones with wild-type
multiplex PCR patterns had potential point
mutations. The frequency of exon deletions in
BD-exposed workers was 27.4% (101/368),
which was signiﬁcantly higher than the 12.5%
(52/415) in control subjects (p < 0.05). The
types of deletion mutants can be divided into
single exon deletions, multiple exon deletions
(2–8 exon deletions), and mutants in which all
nine exons had deletions. The increase in exon
deletions in the BD-exposed group appears to
be mainly the result of an increase in the pro-
portion of multiple exon deletions (56/368,
15.2%) compared with the control group
(23/415, 5.5%; p < 0.05). The multiple exon
deletions can be further divided into continuous
and discontinuous deletions, both of which had
signiﬁcant differences between the BD-exposed
group and the control group (p < 0.05). In
addition, results of PCR analysis showed that
some of the mutants from the same subject had
different mutational spectra (data not shown).
Discussion
In 1996 Hayes et al. (1996) ﬁrst reported the
HPRT gene MF among workers exposed to BD
in China. That study was conducted at Yanshan
Petrochemical Products Co., one of the biggest
petrochemical products corporations in China
located in Beijing in the northern part of
China. The present study was performed at
the Yangzi Petrochemical Products Co.,
another large petrochemical products corpora-
tion located in Nanjing in the eastern part of
China. It should be noted that the solvent for
producing BD is different between these two
plants—acrylonitrile (ACN) in Yanshan
Petrochemical Products Co. and dimethylfor-
mamide (DMF) in Yangzi Petrochemical
Products Co. In addition, the BD production
equipment in the present study was imported
from Japan and has been used to produce BD
since 1987.
According to records kept by the facility
that documented BD air concentrations, the
exposure levels detected in 1991 in this work-
shop ranged from 0 to 4.4 ppm. In 1996 there
were 9 samples that ranged from 3.1 to
24.9 ppm among the 27 total samples col-
lected from 9 locations of the same workshop.
The other 18 samples had BD levels below the
limit of detection (LOD; the minimum expo-
sure dose that could be measured depended on
the analytical method. In China the LOD was
about 0.4 ppm when sampling with syringe,
but 0.2 ppm when sampling with charcoal
tube). In 1998 another study of BD exposure
was carried out in the same workshop. In this
study there were a total of 60 samples collected
from 20 locations with exposure levels ranging
from 0 to 6.0 ppm. In the present study, when
data from all three samplings were considered,
the average value of BD detected was 9.7 ppm.
If we excluded the highest value from the sewer
exit location in the workshop, the other
29 samples ranged from 0 to 25.8 ppm,
and the average value of BD was 7.2 ppm
(Table 1). These BD exposure data are consis-
tent with the historical records for the same
workshop recorded from 1991 to 2001
described above. Comparing this BD exposure
data with other studies, our data indicate that
the BD level is higher than that detected in the
Yanshan Petrochemical Products Co. (Hayes
et al. 1996), in which air levels of BD ranged
from 1–45 ppm, and the median level was
2.0 ppm during routine activities. However,
our data showed much higher BD levels than
those detected in other BD-producing plants,
one in Texas, the other near Prague in the
Czech Republic. In the Texas plant the BD
exposure levels found for workers in the ﬁrst
study were 3.5 ± 7.5 ppm in the high-exposure
areas (Ward et al. 1994). With the improve-
ments made in the plant to reduce the BD
exposure, the average exposure decreased to
1.65 ± 0.52 ppm in the high-exposure areas
and to 0.07 ± 0.03 ppm in the low-exposure
areas, with a median exposure level of
Liu et al.
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Figure 2. Schematic diagram of the distribution of deleted exons in mutants from BD-exposed subjects and control subjects. (A) Control subjects. (B) BD-exposed
subjects.
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Deletion of exon0.41 ppm (Ward et al. 2001). In the plant near
Prague the mean exposure level was 1.76 ppm,
and the individual exposure levels ranged from
0.012 to 19.77 ppm (Tates et al. 1996).
Overall, exposure levels varied widely among
plants of different countries. We presume that
BD exposure levels depend primarily on the
quality of the equipment used to produce BD,
the level of automation present in the plant,
the equipment running time, and length of
time the operators worked in the plant. Our
data showed that the alkenes plant of the
Yangzi Petrochemical Products Co. in China
has one of the highest BD exposure levels
among several reported BD production plants.
Although BD had been identified as a
rodent carcinogen, the evidence supporting a
correlation between BD exposure and HPRT
MF in humans was inconsistent. In this study
we found an increase in HPRT gene MFs
between the BD-exposed workers (18.2 ± 9.4
× 10–6) and the control subjects (12.7 ± 7.3 ×
10–6) by using the T-cell cloning assay. This
43.17% difference was, however, not statisti-
cally significant. Our results were consistent
with those of previous studies in BD-exposed
Chinese workers under lower exposure levels
of BD using the same cloning assay (Hayes
et al. 1996; Zhang et al. 2004). After adjust-
ment by multiple regression analysis for age,
sex, and cloning efﬁciency, Hayes et al. (1996)
found that the adjusted mean MF was 13.6 ×
10–6 in nonexposed workers and 18.0 × 10–6
in BD-exposed workers, which was also not
signiﬁcantly different. Other groups using the
T-cell cloning assay to study BD-exposed
workers in the Czech Republic also failed to
find an increase in HPRT MF, even though
the level of BD exposure was similar to that
used in the studies in the Texas plant
(Albertini et al. 2001; Tates et al. 1996). All
these studies are in contrast to the other studies
using autoradiographic assays, which found a
correlation between BD exposure and HPRT
gene mutation (Ammenheuser et al. 2001;
Ward et al. 1994, 1996, 2001). Ward et al.
(1994) reported the MF increased signiﬁcantly
in these BD-exposed workers compared with
control subjects who worked in nonindustrial
settings. In a subsequent study (Ward et al.
2001), it was demonstrated that the MF in
lymphocytes was significantly higher in the
high-exposure group (10.67 ± 1.5 × 10–6)
compared with the low-exposure group (3.54 ±
0.6 × 10–6; p < 0.001), even though improve-
ments were made in the plant to reduce BD
exposure. These results indicated that the posi-
tive ﬁndings had been observed repetitively in
the series studies in Texas. It also suggested the
differences between mutation assays may be
one of the reasons that resulted in the differ-
ence in the effects of BD exposure.
Thus, because there were contradictory
results from different plants in different
countries, it was unclear whether BD induced
an increase in MF. In 2001 Ward et al. (2001)
reported they had conducted autoradiograghic
assays on cryopreserved lymphocytes from sub-
jects in the Czech Republic concurrently with
their study of workers in Texas and found a
very high MF of the HPRT gene in the Czech
administrative workers who had volunteered to
serve as nonsmoking controls for the study in
Prague. It was proposed that the high MF in
the nonsmoking controls was due, in part, to
very high MFs in a few subjects, some of
whom appeared to have had health problems
or exposure to mutagens other than BD. This
indicates that the selection of control subjects is
an important factor that may determine
whether there is any signiﬁcant difference in
MF of the HPRT gene between exposed and
nonexposed subjects.
It is therefore imperative that more detailed
information be considered when exposure data
are collected and how it is associated with the
individual subjects, including how much of the
variation in MF is attributable to each variable
(e.g., smoking status, health history, exposure
history). In the present study, we evaluated
data from BD-exposed and control subjects
matched for age, sex, work duration, consump-
tion of alcohol and caffeine-containing bever-
ages, and smoking and found no significant
differences between the groups. However, it is
possible that if we had been able to stratify the
BD-exposed and nonexposed populations
according to the extent of exposure (some
combination of measured exposure and years of
work, plus years of smoking, for example), we
could have observed if there was any effect that
may have been lost in the pooled data. Other
authors have paid more attention to these ques-
tions. In one study Ward et al. (2001) divided
the BD-exposed subjects into subgroups
according to smoking status and found that the
MF of the HPRT gene was signiﬁcantly higher
in the high-exposure nonsmokers (8.64 ± 1.6 ×
10–6) than in the low-exposure nonsmokers
(3.46 ± 0.65 × 10–6). However, the highest MF
of HPRT (13.10 ± 2.57 × 10–6) was observed
in the high-exposure smokers. Their ﬁndings
were consistent with those of Podlutsky et al.
(1999), who found a statistically significant
increase in the MF of the HPRT gene between
the smoking group (26.6 ± 18.5 × 10–6) and
the nonsmoking group (18.7 ± 12.0 × 10–6).
These studies indicate that the MF observed in
BD-exposed and nonexposed subjects is also
dependent upon other factors such as diet,
lifestyle, general health status, and exposure to
other genotoxic substances in the ambient envi-
ronment. These factors should be explored in
future studies.
Despite the evidence indicating that BD
has mutagenic effects, the molecular mecha-
nism of its mutagenesis is not understood.
The mutagenicity of major BD metabolites
has been well documented in many in vitro
studies, and analysis of the mutational spectra
in these studies indicates that there is a distinct
difference between EB- and DEB-induced
mutations in the HPRT gene. The genotoxic
potencies of BD metabolites are of the order:
DEB >> EB >> EB-diol. However, there is
controversy about which metabolites are
important for human carcinogenicity.
Although DEB is the most potent muta-
gen, reports have suggested that it is not a sig-
nificant factor in in vivo mutagenesis in
humans (Bond et al. 1995). This is further
corroborated by the presence of smaller quan-
tities of DEB in rats and humans than those
found in mice (Filser et al. 2001; Koc et al.
1999; Walker and Meng 2000). Finally, DEB
and EB differ in their metabolism, mechanism
of DNA interaction, and mutagenic potential.
In our study, we observed a statistically
significant increase in the total number of
HPRT clones with deletions in the BD-exposed
workers compared with the control subjects
(p < 0.05). The increase appeared to be pri-
marily the result of an increase in multiple
exon deletions (p < 0.05), including both con-
tinuous deletions and discontinuous deletions
(Table 4). Our results are in agreement with the
data from Ma et al. (2000), Burkhart-Schultz
and Jones (1997), and Burkhart-Schultz et al.
(1996). Analysis of the in vitro mutational spec-
tra of DEB- and EB-induced mutants in a
study by Steen et al. (1997a. 1997b) clearly
revealed that a decrease in the proportion of
single-base substitutions was associated with an
increase in the proportion of large deletion
mutations Our data and similar findings by
Meng et al. (2004) indicate that it is not neces-
sary to invoke the formation of DEB as the sole
source of large exon deletions; rather, HPRT
spectra data from rats indicate that EB-diol is a
likely source of deletion mutations.
In summary the results of the exposure
assessment study indicate the BD occupational
exposure of workers in China is relatively high,
when the data are compared with those from
studies conducted of other countries. Thus, we
suppose that the increases of exon deletions in
the mutants from exposed workers likely repre-
sent the mutations induced by BD. In a previ-
ous study Ma et al. (2000) further used HPRT
coding sequence analysis and compared the
molecular mutational spectrum of BD-exposed
workers with those of control subjects. The
authors identiﬁed a lower frequency of single-
base substitutions, a higher proportion of
A:T→T:A transversions and ± 1 frameshift
mutations in BD-exposed workers. These
changes were also confirmed by Meng et al.
(2004) in mice and rats. In the future, we plan
to analyze more population samples and molec-
ular mutational spectrums in order to elucidate
the molecular mutational spectrum associated
with butadiene exposure.
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